Eva Fortea Verdejo's Stock Ratings Wells Fargo Analyst Eva Fortea Verdejo is an analyst at Wells Fargo. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating ...

In a report released yesterday, Eva Fortea Verdejo from Wells Fargo maintained a Buy rating on Zymeworks, with a price target of $34.00. The company’s shares closed yesterday at $24.54. Unlock trusted ...

We just received data on a new analyst forecast for $BCAX. Eva Fortea Verdejo from Wells Fargo set a price target of 8.0 for BCAX. Multiple analysts have issued price ...

Detailed price information for Revolution Medicines Inc (RVMD-Q) from The Globe and Mail including charting and trades.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) is one of the most promising mid-cap healthcare stocks under $50. On December 12, Wells Fargo analyst Eva Fortea Verdejo indicated her bullish ...

$RCUS insiders have traded $RCUS stock on the open market 4 times in the past 6 months. Of those trades, 3 have been purchases and 1 have been sales. Here’s a ...

Wells Fargo analyst Eva Fortea Verdejo initiated coverage of Xencor (XNCR) with an Overweight rating and $37 price target The firm doesn’t think the Street is pricing in enough value for Xencor’s ...

Eva Fortea Verdejo is an analyst at Wells Fargo. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future ...